GlassScriptPhysician profile
Hetain N Patel
NPI 1710227954
$25,398.46
in general payments reported to CMS, 2019-2025
25 companies · $4,370 in 2025
The $4,370 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,399 · 2020: $1,155 · 2021: $1,170 · 2022: $2,158 · 2023: $6,504 · 2024: $6,643 · 2025: $4,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $16K · Food and Beverage: $1,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $15,733.33 |
| Food and Beverage | $1,782.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $15,733.33 | 2023-2025 | Auryon Laser System 100-120 Vac |
| Abbott Laboratories | $2,652.09 | 2019-2022 | |
| Boston Scientific Corporation | $1,646.80 | 2019-2023 | Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $905.59 | 2019-2025 | Farxiga, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $887.27 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $503.64 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $472.87 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $403.71 | 2019-2024 | Xarelto |
| Pfizer INC. | $283.36 | 2019-2022 | |
| Medtronic, INC. | $275.96 | 2021-2024 | Aurora Ev-Icd Mri Surescan, Corevalve Evolut R |
| Astellas Pharma US INC | $273.14 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $242.28 | 2020-2023 | Camzyos |
| Medtronic Vascular, INC. | $136.96 | 2019-2020 | |
| Cardiva Medical, INC. | $129.87 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Amag Pharmaceuticals, INC. | $124.95 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $124.66 | 2019 | |
| Esperion Therapeutics, INC. | $114.79 | 2021 | |
| Philips North America LLC | $114.65 | 2025 | Coronary Other |
| Seagen INC. | $92.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $73.27 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.15 | 2022-2023 | Jardiance |
| Amgen INC. | $57.33 | 2019-2025 | Repatha, Repatha |
| Abiomed | $50.38 | 2025 | |
| Bridgebio Pharma, INC. | $19.55 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $13.81 | 2023 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hetain Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.